IFNB1 and myeloid sarcoma: Randomized clinical trials in relapsing-remitting MS patients did not report significant immune regulatory effects of high doses of vitamin D in MS patients (21–23), although the effect could have been at least partially masked by the concomitant IFN-β treatment.